NUCLEOLIN and cancer: Recently, the aptamer AS1411 has been used to target cancer cells overexpressing glycosylated nucleolin on their cell surface and has entered clinical phases (Laber et al., 2007; Rizzieri et al., 2010; Koutsioumpa and Papadimitriou, 2014).